Spännande dag imorgon – miljömöten på LIF hela dagen

SWEDISH SUMMARY: Imorgon fredag har vi flera spännande möten på LIF. Under förmiddagen har vi först ett möte tillsammans med Läkemedelsverket där vi diskuterar möjliga konsekvenser av de svenska miljömålen gällande läkemedel i miljön, därefter träffas vi som arbetar med att utveckla indikatorer för Nationella läkemedelsstrategins miljöinitiativ. På eftermiddagen har sedan LIF:s Expertgrupp Miljö möte. Jag ser fram emot intressanta diskussioner!

I am looking forward to several interesting meetings tomorrow at LIF (the association of the research-based pharmaceutical industry). In the morning we will first meet Swedish MPA and discuss potential consequences of the Swedish national environmental objectives concerning pharmaceuticals in the environment (PiE). Examples of those objectives are to bring the environmental risk assessments (ERAs) in to the risk/benefit evaluation (i.e. the authorization process of pharmaceuticals) and the inclusion of environmental standards to GMP (Good Manufacturing Practices). As you know since previous blog posts, I have concerns in relation to those objectives. We must never ever forget that patient access to valuable medicines is paramount! You also know that I strongly believe that industry’s Eco-Pharmaco Stewardship proposal (see for instance the blog post from Sept 12) will bring the environmental benefits we are all looking for.

Then before lunch I will meet with the group developing environmental indicators for the National Pharmaceutical Strategy. We will both look into the work already done on quality assuring monitoring results on pharmaceutical occurance in the Swedish environment, and discuss additional indicators for future development.

And then after lunch I will meet with LIF’s Expert Group Environment. I of course expect very interesting discussions there as well!

Looking forward to tomorrow!

Diskussioner om läkemedel i miljön med EU kommissionen

SWEDISH SUMMARY: Igår genomförde EU kommissionen (under ledning av DG Environment) en stor work-shop i Bryssel, med över 130 deltagare, gällande läkemedel i miljön. Huvudfokus för diskussionerna var de olika förslagen på möjliga åtgärder föreslagna i den så kallade BIO-IS-rapporten - spännande och intressant! Vi fick från industrins sida flera möjligheter att föra fram vårt initiativ Eco-PharmacoStewardship, EPS (som jag tidigare kort beskrivit här på bloggen exempelvis 18 maj). Min uppfattning är att EPS adresserar flera av de tyngsta åtgärdsförslagen i BIO-IS-rapporten.

Yesterday the EU commission (more specifically DG Environment in collaboration with DG Sanco) run a workshop with more than 130 delegates in Brussels. The topic was pharmaceuiticals in the environment (PiE) in general and the so called BIO-IS report specifically. The workshop forms an important basis for the development of the PiE Strategy from the commission which is due for fall next year. There were participants from different authorities and agencies around Europe, from several NGOs, from academia, and from the pharmaceutical industry (both human medicines and veterinary medicines). The workshop run i three sequential sessions focusing three main themes of options/actions proposed in the BIO-IS report:

- Options relevant to product’s development, authorization, production

- Options relevant to product consumption and use

- Options relevant to disposal

 In each session we broke up into ten smaller groups to discuss and prioritize proposals for actions from the report, and were also asked to add any additional option we thought was worth considering. I have to say that I was very impressed by the work process! Very good, open and relevant discussions were held and we were able to come up with clear priority lists.

I was very happy that we had several good possibilities to share industry’s ideas on an Eco-Pharmaco Stewardship (EPS) initiative. I have discussed the EPS initiative briefly in blog posts previously (e.g. on May 18). It is my clear opinion that the EPS initiative addresses several of the more important options presented in the BIO-IS report.

Näringslivslunch hos Sollentuna Kommun – om CSR-initiativ

Sollentuna kommunvapen - compressed

SWEDISH SUMMARY: Idag deltog jag i Sollentuna Kommuns näringslivslunch. Jag var tillsammans med företrädare för 3 andra företag i kommunen inbjuden att berätta om Pfizers CSR-strategi och -arbete. Bra diskussioner och förhoppningsvis en nystart av en djup samverkan mellan näringsliv, kommun och frivilligorganisationer.

I was invited today to Sollentuna Municipality’s ”enterprise lunch” together with representatives from three other companies to talk about CSR-strategies and CSR-programs. In addition to myself, Johnson&Johnson was represented by Erika Kruse, SVEAB by Tobias Andersson, and Nordea by Poya Motai – all of them giving nice examples on what CSR is all about.

My opinion is that CSR-initiatives should,  to be sustainable and valuable for both society and for the business, be linked to the core business. Hence, Pfizer’s initiatives are connected to health and prevention of illnesses. It is also my opinion that we should have global, as well as national and local initiatives. I have over the years presented several of our CSR-initiatives here at the blog.

Examples of Pfizer global initiatives could be our work to fight illnesses in Africa. National examples could be our work on tobacco prevention and the fight against cancer.

When it comes to initiatives connected in one way or another to Sollentuna municipality there are several examples:

- With an environmental sustainability angle: Earth Hour engagement and the environmental profile of our office building in Sollentuna.

- With a social sustainability angle: Collaborations with local schools (Helenelundsskolan and Rudbeck), with organizations such as Swedish church and ”Sollentuna women’s shelter

I hope that today’s discussions will drive further development of interesting CSR-initiatives, in strong collaboration between with Sollentuna’s companies, NGOs and the municipality!

 

 

Styrelsemöte i CSR Sweden – det har gått 10 år sen starten, mycket har hänt…

csr-sweden-logga

SWEDISH SUMMARY: Idag hade vi styrelsemöte i CSR Sweden. Vi diskuterade bland mycket annat CSR Swedens verksamhet och dess olika evenemang och utbildningar. Det blev en intressant diskussion om, och reflektion över, de tio år som har passerat sen CSR Sweden bildades. Den generella uppfattningen om CSR var verkligen annorlunda på den tiden. Många kopplade samman CSR nästan uteslutande med välgörenhet. Idag finns en mycket tydligare koppling till affärsverksamheten. Vad tror ni CSR betyder om tio år? Vilket förändring kommer att ske inom CSR och hållbarhetsområdet fram emot 2025?

The board of CSR Sweden met earlier today for a board meeting.  In addition to common boeard meeting agenda items, e.g. finacials, review of ongoing operations, events and training sessions, we also shortly reflected upon the fact that CSR Sweden was created 10 years ago. The ”CSR issue” has really changed during this time period. Ten years ago, a lot of people still regarded CSR ”a charity thing”. Today we see a much stronger link to the core business strategies. And interesting of course is then to elaborate upon where CSR and sustainability will be in ten years, let’s say 2025. I promise to come back with some of my thoughts on that theme during fall – but first, please give me your ideas on ”CSR in 2025″.

Miljödiskussioner med Estlands läkemedelsverk

SWEDISH SUMMARY: Jag har idag haft intressanta diskussioner gällande läkemedel i miljön, med representanter från Estlands läkemedelsverk i samband med deras besök på Läkemedelsverket. En enkel slutsats från dagens diskussion är att den generella medvetenheten och förståelsen i samhället om hälso- och sjukvårdens samt läkemedelssektorns miljöfrågeställningar är större på vår sida av Östersjön.

 I have today met with representatives of Estonia’s MPA (Medical Products Agency) to discuss pharmaceuticals in the enviroment (PiE). The Estonian MPA has been on a three day visit to Sweden, hosted by Swedish MPA, to discuss environmental issues with a range of Swedish stakeholders, e.g. EPA and MPA, Ministry of Environment, Stockholm County Council, Akademiska hospital in Uppsala, and the industry. I gave them the perspectives of the industry on pharmaceuticals in the environment, with examples of initiatives from both the Swedish pharmaceutical association LIF, and the European association EFPIA.

Examples of LIF initiatives are the environmental classification of pharmaceutical substances on Fass.se, and the development of an environmental assessment model for pharmaceutical products. The EFPIA initiative presented was the EcoPharmacoStewardship initiative (EPS).

It was obvious from the discussions that the general awareness in society of PiE and other environmentally related issues within healthcare and the pharmaceutical sector are more common in Sweden than in Estonia. However, the interest from the Estonian visitors was great, and their personal knowledge impressive, hence and I look forward to meeting them again and take the discussions further.